Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial

OBJECTIVE: To estimate the incremental cost-effectiveness of infliximab versus conventional combination treatment over 21 months in patients with methotrexate-refractory early rheumatoid arthritis. METHODS: In this multicentre, two-arm, parallel, randomised, active-controlled, open-label trial, rheu...

Descripción completa

Detalles Bibliográficos
Autores principales: Eriksson, Jonas K, Karlsson, Johan A, Bratt, Johan, Petersson, Ingemar F, van Vollenhoven, Ronald F, Ernestam, Sofia, Geborek, Pierre, Neovius, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4431324/
https://www.ncbi.nlm.nih.gov/pubmed/24737786
http://dx.doi.org/10.1136/annrheumdis-2013-205060

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4431324/
https://www.ncbi.nlm.nih.gov/pubmed/24737786
http://dx.doi.org/10.1136/annrheumdis-2013-205060

Ejemplares similares